CION Ameerpet
Endometrioid carcinoma is the second commonest form of ovarian cancer, and it does not behave like the subtype most statistics describe. It is graded rather than high-grade by definition, it is more often confined when it is found, and it is linked to endometriosis far more often than to BRCA. Each of those differences changes what your treatment plan should look like.
The name describes what the cells look like, not where they came from. Endometrioid means they resemble the lining of the womb — the endometrium — even though the tumour is sitting in the ovary. That is the whole of the word. It identifies the second commonest form of epithelial ovarian cancer, after high-grade serous.
The resemblance is not a coincidence. A large proportion of these cancers arise in endometrial-type tissue that is growing in the wrong place: endometriosis, and particularly a long-standing ovarian endometrioma. That is one of two reasons endometrioid ovarian carcinoma is often diagnosed in women a good deal younger than the average for ovarian cancer. The other is that it more often causes trouble — and gets scanned — while still confined.
This matters because almost everything you will read after searching ovarian cancer is describing high-grade serous: the late presentation, the BRCA testing, the maintenance therapy, the survival figures. Some of it applies to you and some of it does not. This subtype is graded rather than high-grade by definition, is frequently hormone-receptor positive, and has a mismatch repair question attached to it that high-grade serous does not. Those differences are the practical content of this page.
The cells resemble the lining of the womb. It tells you what the pathologist saw, not that the cancer started in your uterus.
After high-grade serous. Much of what is written about “ovarian cancer” is describing that other subtype rather than this one.
A larger share of endometrioid cancers are found at stage I or II, when disease is contained and treatment is shorter.
When endometrioid carcinoma is found in an ovary, a second endometrioid cancer is sometimes found in the lining of the womb at the same time. For decades that combination was read as one tumour having spread to the other — which would have made it advanced disease and triggered treatment to match. Molecular studies changed the reading: the two tumours are frequently related, and yet these women do far better than the apparent stage predicts. Synchronous endometrioid carcinoma of the endometrium and ovary is now treated in most cases as two independent early-stage primaries. It is precisely why an endometrial biopsy belongs in the work-up of an endometrioid ovarian tumour, rather than being an afterthought. Source: WHO Classification of Tumours, Female Genital Tumours (5th edition); NCCN Ovarian Cancer guidelines.
Six features separate endometrioid carcinoma from the other epithelial subtypes, and every one of them has a practical consequence for your treatment plan.
| Feature | What it means | Why it matters |
|---|---|---|
| Frequently arises in endometriosis | Endometrioid and clear cell are the two subtypes that develop within endometriotic tissue. | It explains the younger age at diagnosis, and why an endometrioma that changes on scan is taken seriously. Compare clear cell ovarian carcinoma. |
| Graded 1, 2 or 3 | High-grade serous is high-grade by definition. This subtype is graded, and the grade varies. | Grade and stage together decide whether chemotherapy is recommended at all. |
| Often confined when found | A larger share is diagnosed at stage I or II than with high-grade serous. | Complete surgical staging becomes the single most consequential step, because everything after depends on it. |
| Frequently hormone-receptor positive | The tumour cells often carry oestrogen and progesterone receptors. | Hormonal treatment has a real role in selected low-grade and recurrent disease — a lever high-grade serous rarely offers. |
| Mismatch repair loss in a meaningful minority | Loss of MMR proteins on the tumour, or microsatellite instability. | It points to Lynch syndrome, changes testing for your family, and carries treatment implications. |
| A second cancer in the uterus is not rare | Synchronous endometrioid carcinoma of the endometrium and the ovary. | The uterus is checked as part of the work-up. See endometrial (uterine) cancer. |
| CA-125 is less reliable here | It is not raised as consistently as it is in high-grade serous carcinoma. | A normal CA-125 does not reassure in this subtype, and it is a weaker tool for monitoring afterwards. |
*BRCA and HRD dominate the conversation in high-grade serous and are less central here, though germline testing is still offered to women with epithelial ovarian cancer. In this subtype it is the mismatch repair result that most often changes something.
Surgery comes first in most cases, and what follows it is decided by two numbers on the pathology report: the grade and the stage. Some women in this group need no chemotherapy at all.
The operation removes the tumour and, in the same sitting, establishes the stage — washings taken, the peritoneum and omentum inspected and sampled, lymph nodes assessed where indicated. In a subtype that is frequently confined at diagnosis, this is not paperwork. An incompletely staged tumour can look better on paper than it is, and every decision afterwards rests on a number that was never properly established.
This is why who performs the operation matters. At CION, staging and debulking surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — we arrange it that way because outcomes are better in specialist hands, and we would rather say so plainly than let you discover it at the billing counter.
This is the question that separates endometrioid carcinoma from most of what you have been reading. Where the disease is confined to one ovary, the grade is low and the surgical staging was complete, careful surveillance without chemotherapy is an accepted option rather than a corner being cut. Where the grade is higher, or disease has extended beyond the ovary, platinum-based chemotherapy after surgery is standard.
Chemotherapy, when it is needed, is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, so treatment can continue near where you live rather than requiring repeated travel while you are unwell. What we will not do is give chemotherapy to be seen to be doing something. If the honest answer is that surveillance is enough, that is the answer you will get.
Endometrioid tumours are frequently hormone-receptor positive, meaning the cells carry oestrogen and progesterone receptors and can be influenced by blocking or altering that signal. This is why hormonal treatment has a genuine place in selected low-grade and recurrent endometrioid disease, and almost none in high-grade serous.
It is generally better tolerated than chemotherapy, which makes it useful over longer periods, and it is delivered in-house at CION. Whether it applies to you depends on the receptor status recorded on your pathology report — worth asking about specifically, because it is not always mentioned unless someone raises it.
The tumour tissue is tested for the mismatch repair proteins, or for microsatellite instability. Loss is found in a meaningful minority of endometrioid ovarian cancers and is the most useful single pointer towards Lynch syndrome, an inherited condition that also raises the risk of endometrial and bowel cancer.
An abnormal tumour result leads to germline testing and genetic counselling, both delivered in-house at CION. The consequences run in two directions: it can change what treatment is available to you, and it changes what screening your siblings and children should be offered. If nobody has mentioned this test, ask whether it has been done.
Because endometrioid carcinoma can arise in the womb lining and the ovary at once, the endometrium is assessed as part of the work-up — by outpatient sampling, or at the time of surgery. Finding a second endometrioid cancer there does not automatically mean the disease has spread; in most cases the two are handled as independent early-stage primaries.
It does mean the plan is made with both organs in view, and it is another reason abnormal bleeding is never dismissed in a woman with this diagnosis. For the wider picture on the other disease, see endometrial (uterine) cancer.
Endometrioid carcinoma is diagnosed in younger women more often than high-grade serous, so this question comes up genuinely rather than theoretically. In carefully selected early, low-grade disease confined to one ovary, fertility-sparing surgery that preserves the uterus and the other ovary can be an option, with complete staging still performed.
It is a decision for a specialist gynaecologic-oncology surgeon and it narrows sharply if the uterus is also involved. At CION this surgery is coordinated with partner centres and may be billed there. Raise it at the first consultation rather than after the operation — it is one of the few things that cannot be revisited later.
These come up constantly in second opinions and are frequently not covered unless someone asks. None of them is an awkward question.
Both are on the report and both change the plan. If the grade is not stated clearly, that is worth chasing.
Washings, omentum, peritoneal sampling, nodes where indicated. A confined tumour is only confined if it was properly looked for.
It is done on tissue already removed, points to Lynch syndrome, and can change what treatment is available.
A synchronous endometrial cancer is well recognised in this subtype and is looked for rather than assumed absent.
In completely staged, low-grade, confined disease, surveillance can be the right answer. Ask for the reasoning either way.
Multidisciplinary review before a plan is set is standard practice, not an optional extra you have to request.
If your plan was decided without a grade, without confirmation that staging was complete, or without a mismatch repair result, those are gaps worth raising rather than assuming somebody considered them.
Grade, stage and mismatch repair status decide whether you need chemotherapy at all. Bring the report — 45 minutes is long enough to read it line by line and tell you what it actually says.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, hormonal treatment, genetic counselling and Lynch syndrome testing are all delivered in-house at CION.
Of everything on this page, this is the finding that frightens women most and needs the least fear attached to it. Two endometrioid cancers found at once is a recognised pattern with a well-established meaning.
The intuitive reading — that the ovarian tumour travelled to the womb, or the reverse — would make this advanced disease. That is not how it is understood. Where both tumours are endometrioid, both low grade and both confined to their own organ, they are treated in the great majority of cases as two independent early-stage cancers. The staging reflects that, and so does the treatment.
Women with synchronous endometrioid carcinoma of the endometrium and ovary consistently do better than the apparent extent of disease would predict. It is one of the clearest examples in gynaecologic oncology of why the pathology matters more than the count of organs involved. If you have been told there is cancer in two places, ask specifically whether they are being managed as synchronous primaries.
Because the association is well known, the endometrium is assessed when endometrioid carcinoma is found in an ovary — by outpatient sampling or at the time of surgery. It is also why abnormal bleeding, and any bleeding at all after the menopause, is investigated rather than watched. The full picture on the other disease is set out in our guide to endometrial (uterine) cancer.
Endometrioid cancer of the ovary and of the endometrium are both part of the Lynch syndrome spectrum, along with bowel cancer. That is one more reason the mismatch repair test on the tumour is worth insisting on, and why a positive germline result changes screening for your relatives as much as your own follow-up. See Lynch syndrome and ovarian cancer.
Everyone diagnosed looks for the numbers, and there is no point pretending otherwise. The useful thing is to know how the published figures are built, because for this subtype they mislead in three specific ways.
They are averaged across subtypes — most large ovarian cancer survival figures are dominated by high-grade serous, which presents later, so they understate what confined low-grade endometrioid disease looks like. They are averaged across grades and stages, so a grade 1 tumour confined to one ovary and a grade 3 tumour that has spread sit inside the same percentage. And they are historical, describing women treated years ago, before routine mismatch repair testing and current treatment pathways. On top of that, older series mix completely staged and incompletely staged surgery together, which quietly changes the numbers on both sides.
CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. Those are one-year figures across the whole treated population — not cure rates, and not a prediction for any individual. What your own outlook looks like depends on grade, on stage, on whether staging was complete, and on your general health, and it is a conversation to have with the oncologist who can see all four.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
General ovarian cancer figures are dominated by high-grade serous, which presents later than endometrioid disease.
Grade, stage, completeness of staging and your own health matter far more to your outlook than any published percentage.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
This subtype rewards a careful reading of the pathology report more than almost any other, because the report is what decides whether you are treated or watched. Grade, stage, completeness of staging, hormone receptor status, mismatch repair result — five things, and in a rushed clinic two or three of them get skipped. Your first consultation at CION is free and runs to about 45 minutes, which is long enough to go through the report line by line with you.
What CION delivers in-house lines up with what this subtype needs after surgery: chemotherapy where it is warranted, hormonal treatment where the receptors support it, and genetic counselling and testing once the tumour's mismatch repair result is known — across 35+ centres in Telangana and Andhra Pradesh, so follow-up happens near where you live. Every case that raises a question goes to a tumour board rather than being decided by one doctor.
Staging and debulking surgery, including fertility-sparing surgery where it is being considered, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. We state that at the start. Surgery in this subtype carries more weight than usual, because a confined tumour is only confined if it was staged properly, and that is work for a specialist gynaecologic-oncology surgeon. Where the plan turns out to be surveillance rather than treatment, we will tell you that plainly too — decisions for healing, not billing.
Free, and long enough to read your pathology report properly rather than glance at the headline diagnosis.
In completely staged, low-grade, confined disease, surveillance can be the right plan. We will say so when it is.
Genetic counselling, Lynch syndrome testing, chemotherapy and hormonal treatment all delivered in-house at CION.
Staging, debulking and fertility-sparing surgery at specialist gynaecologic-oncology partner centres, and may be billed there.
It is a type of ovarian cancer named for what the cells look like under the microscope: they resemble the lining of the womb, the endometrium, even though the tumour is in the ovary. It is the second commonest form of epithelial ovarian cancer after high-grade serous, and it behaves differently from that subtype in ways that matter practically. It is graded 1, 2 or 3 rather than being high-grade by definition. A larger share is found at stage I or II. It frequently arises within endometriosis, and it is frequently hormone-receptor positive, which gives treatment an extra option. Most of the survival figures you will find online are describing high-grade serous rather than this.
As a group, yes — but the honest answer is that grade and stage decide that, not the subtype name. A low-grade tumour confined to one ovary behaves very differently from grade 3 disease that has spread beyond the pelvis, even though both carry the same subtype label on the report. Endometrioid cancers are found earlier and are more often low grade than high-grade serous, which is why the group as a whole does better. What it means for you is written in two places on your pathology report: the grade, and the surgical stage. Ask for both, and ask whether the staging was complete, because an incompletely staged tumour can look better on paper than it actually is.
No. Endometriosis is common and ovarian cancer is not, and the overwhelming majority of women with endometriosis never develop it. What is true is that two ovarian cancer subtypes, endometrioid and clear cell, can arise within endometriotic tissue, so the relative risk is modestly raised while the absolute risk stays low. That is not a reason for surveillance scans, because no screening test has been shown to reduce deaths from ovarian cancer in anyone. It is a reason to take a change seriously: an endometrioma that grows, develops solid areas or new blood flow on ultrasound, or pelvic pain that changes character after years of a familiar pattern, deserves a look rather than being filed under the endometriosis.
Because endometrioid carcinoma can arise in both places at once, and this is a recognised pattern rather than a surprise. For decades a tumour in the ovary alongside one in the womb lining was read as one having spread to the other, which would have made the disease advanced. Molecular work changed that reading: the two are frequently related, and yet women with this combination consistently do better than the apparent stage would predict. In the great majority of cases they are now treated as two independent early-stage primaries. It is also why an endometrial biopsy belongs in the work-up when endometrioid carcinoma is found in an ovary, and why the plan is made with both organs in view.
Grade describes how closely the tumour cells still resemble normal glandular tissue and how quickly they are dividing. Grade 1 cells look relatively organised and grow slowly, grade 3 look markedly abnormal and grow faster, and grade 2 sits between them. Unlike high-grade serous carcinoma, which is high-grade by definition, endometrioid carcinoma is graded, and the grade carries real weight. Together with the surgical stage it decides whether chemotherapy is recommended at all: completely staged low-grade disease confined to one ovary may be followed with surveillance alone, while a higher grade or more extensive disease is usually treated with platinum-based chemotherapy after surgery. If your report does not state a grade clearly, ask — it is not a detail.
The tumour should be tested first, and that is standard practice. Pathologists check the mismatch repair proteins on the tissue already removed, or test for microsatellite instability. Loss is found in a meaningful minority of endometrioid ovarian cancers and is the single most useful pointer to Lynch syndrome, an inherited condition that also raises the risk of endometrial and bowel cancer. If the tumour test is abnormal, germline testing and genetic counselling follow, and a positive result changes screening for your siblings and children as much as your own follow-up. Mismatch repair status can also have treatment implications. Genetic counselling and testing are delivered in-house at CION. If nobody has mentioned it, ask whether it has been done.
The first consultation is free and runs to about 45 minutes — bring your pathology report and any imaging. Chemotherapy and hormonal treatment are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, as are genetic counselling and the germline testing that follows an abnormal mismatch repair result. Staging and debulking surgery, including fertility-sparing surgery where that is being considered, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Outcomes are better when this surgery is done by a specialist gynaecologic-oncology surgeon, which is why it is arranged that way, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.